Recombinant human thyroid stimulating hormone does not acutely change serum osteoprotegerin and soluble receptor activator of nuclear factor-kappaBeta ligand in patients under evaluation for differentiated thyroid carcinoma.

Massimo Giusti, Francesca Cecoli, Carla Ghiara, Alessandro Rubinacci, Isabella Villa, Domenico Cavallero, Laura Mazzuoli, Michele Mussap, Roberto Lanzi, Francesco Minuto

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: Some extra-thyroid actions of thyroid stimulating hormone (TSH), such as an in vitro action on bone, have been described. Our aim was to evaluate in vivo the acute effect of a recombinant human TSH (rhTSH)-induced TSH surge on Osteoprotegerin (OPG) and receptor activator of the nuclear factor-kappaBeta (RANK-L) levels in patients under levo-thyroxine (L-T4) therapy. DESIGN: 24 patients with differentiated thyroid carcinoma (DTC) were studied. Standard rhTSH testing was performed. OPG, RANK-L, TSH, thyroid hormones, thyroglobulin and several parameters of bone metabolism were evaluated. RESULTS: Baseline OPG and RANK-L levels were in the range of our reference population. An inverse correlation between OPG and spinal Z-score (p=0.029) and between RANK-L and age (p=0.018) or urinary calcium/creatinine ratio (p=0.011) was detected. After rhTSH administration, a significant (p

Original languageEnglish
Pages (from-to)304-313
Number of pages10
JournalHormones
Volume6
Issue number4
Publication statusPublished - Oct 2007

Fingerprint

Osteoprotegerin
Thyrotropin
Cytoplasmic and Nuclear Receptors
Thyroid Neoplasms
Thyrotropin Alfa
Ligands
Serum
Bone and Bones
Thyroglobulin
Thyroxine
Thyroid Hormones
Creatinine
Thyroid Gland
Reference Values
Calcium
Population
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Recombinant human thyroid stimulating hormone does not acutely change serum osteoprotegerin and soluble receptor activator of nuclear factor-kappaBeta ligand in patients under evaluation for differentiated thyroid carcinoma. / Giusti, Massimo; Cecoli, Francesca; Ghiara, Carla; Rubinacci, Alessandro; Villa, Isabella; Cavallero, Domenico; Mazzuoli, Laura; Mussap, Michele; Lanzi, Roberto; Minuto, Francesco.

In: Hormones, Vol. 6, No. 4, 10.2007, p. 304-313.

Research output: Contribution to journalArticle

Giusti, Massimo ; Cecoli, Francesca ; Ghiara, Carla ; Rubinacci, Alessandro ; Villa, Isabella ; Cavallero, Domenico ; Mazzuoli, Laura ; Mussap, Michele ; Lanzi, Roberto ; Minuto, Francesco. / Recombinant human thyroid stimulating hormone does not acutely change serum osteoprotegerin and soluble receptor activator of nuclear factor-kappaBeta ligand in patients under evaluation for differentiated thyroid carcinoma. In: Hormones. 2007 ; Vol. 6, No. 4. pp. 304-313.
@article{f7e46c996de84ada83a4ae3cc266ce3b,
title = "Recombinant human thyroid stimulating hormone does not acutely change serum osteoprotegerin and soluble receptor activator of nuclear factor-kappaBeta ligand in patients under evaluation for differentiated thyroid carcinoma.",
abstract = "OBJECTIVE: Some extra-thyroid actions of thyroid stimulating hormone (TSH), such as an in vitro action on bone, have been described. Our aim was to evaluate in vivo the acute effect of a recombinant human TSH (rhTSH)-induced TSH surge on Osteoprotegerin (OPG) and receptor activator of the nuclear factor-kappaBeta (RANK-L) levels in patients under levo-thyroxine (L-T4) therapy. DESIGN: 24 patients with differentiated thyroid carcinoma (DTC) were studied. Standard rhTSH testing was performed. OPG, RANK-L, TSH, thyroid hormones, thyroglobulin and several parameters of bone metabolism were evaluated. RESULTS: Baseline OPG and RANK-L levels were in the range of our reference population. An inverse correlation between OPG and spinal Z-score (p=0.029) and between RANK-L and age (p=0.018) or urinary calcium/creatinine ratio (p=0.011) was detected. After rhTSH administration, a significant (p",
author = "Massimo Giusti and Francesca Cecoli and Carla Ghiara and Alessandro Rubinacci and Isabella Villa and Domenico Cavallero and Laura Mazzuoli and Michele Mussap and Roberto Lanzi and Francesco Minuto",
year = "2007",
month = "10",
language = "English",
volume = "6",
pages = "304--313",
journal = "Hormones",
issn = "1109-3099",
publisher = "Hellenic Endocrine Society",
number = "4",

}

TY - JOUR

T1 - Recombinant human thyroid stimulating hormone does not acutely change serum osteoprotegerin and soluble receptor activator of nuclear factor-kappaBeta ligand in patients under evaluation for differentiated thyroid carcinoma.

AU - Giusti, Massimo

AU - Cecoli, Francesca

AU - Ghiara, Carla

AU - Rubinacci, Alessandro

AU - Villa, Isabella

AU - Cavallero, Domenico

AU - Mazzuoli, Laura

AU - Mussap, Michele

AU - Lanzi, Roberto

AU - Minuto, Francesco

PY - 2007/10

Y1 - 2007/10

N2 - OBJECTIVE: Some extra-thyroid actions of thyroid stimulating hormone (TSH), such as an in vitro action on bone, have been described. Our aim was to evaluate in vivo the acute effect of a recombinant human TSH (rhTSH)-induced TSH surge on Osteoprotegerin (OPG) and receptor activator of the nuclear factor-kappaBeta (RANK-L) levels in patients under levo-thyroxine (L-T4) therapy. DESIGN: 24 patients with differentiated thyroid carcinoma (DTC) were studied. Standard rhTSH testing was performed. OPG, RANK-L, TSH, thyroid hormones, thyroglobulin and several parameters of bone metabolism were evaluated. RESULTS: Baseline OPG and RANK-L levels were in the range of our reference population. An inverse correlation between OPG and spinal Z-score (p=0.029) and between RANK-L and age (p=0.018) or urinary calcium/creatinine ratio (p=0.011) was detected. After rhTSH administration, a significant (p

AB - OBJECTIVE: Some extra-thyroid actions of thyroid stimulating hormone (TSH), such as an in vitro action on bone, have been described. Our aim was to evaluate in vivo the acute effect of a recombinant human TSH (rhTSH)-induced TSH surge on Osteoprotegerin (OPG) and receptor activator of the nuclear factor-kappaBeta (RANK-L) levels in patients under levo-thyroxine (L-T4) therapy. DESIGN: 24 patients with differentiated thyroid carcinoma (DTC) were studied. Standard rhTSH testing was performed. OPG, RANK-L, TSH, thyroid hormones, thyroglobulin and several parameters of bone metabolism were evaluated. RESULTS: Baseline OPG and RANK-L levels were in the range of our reference population. An inverse correlation between OPG and spinal Z-score (p=0.029) and between RANK-L and age (p=0.018) or urinary calcium/creatinine ratio (p=0.011) was detected. After rhTSH administration, a significant (p

UR - http://www.scopus.com/inward/record.url?scp=38849188023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38849188023&partnerID=8YFLogxK

M3 - Article

C2 - 18055421

AN - SCOPUS:38849188023

VL - 6

SP - 304

EP - 313

JO - Hormones

JF - Hormones

SN - 1109-3099

IS - 4

ER -